Erratum: Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma (Trends in Pharmacological Sciences (2015) 36 (688-704) DOI: 10.1016/j.tips.2015.06.010);Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma

Trends in Pharmacological Sciences

Volumn 36, Issue 10, 2015, Pages 688-704

  Sauer, Sascha ^a,b  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12 14 PGJ2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMORFRUTIN A; AMORFRUTIN B; LIGAND; MESALAZINE; MRL 24; OLSALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SR 1664; SR 1824; TELMISARTAN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; PROTEIN BINDING;

BINDING AFFINITY; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM;

ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; PPAR GAMMA; PROTEIN BINDING; THIAZOLIDINEDIONES;

EID: 84943411002     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.12.002     Document Type: Erratum

References (106)

1. D.J. Mangelsdorf, and et al. The nuclear receptor superfamily: the second decade Cell 83 1995 835 839
2. M. Fu, and et al. A Nuclear Receptor Atlas: 3T3-L1 adipogenesis Mol. Endocrinol. 19 2005 2437 2450
3. M.A. Lazar PPAR gamma, 10 years later Biochimie 87 2005 9 13
4. C.J. Rosen Revisiting the rosiglitazone story - lessons learned N. Engl. J. Med. 363 2010 803 806
5. G.D. Barish, and et al. A Nuclear Receptor Atlas: macrophage activation Mol. Endocrinol. 19 2005 2466 2477
6. M. Lehrke, and M.A. Lazar The many faces of PPARgamma Cell 123 2005 993 999
7. G. Medina-Gomez, and et al. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1) Public Health Nutr. 10 2007 1132 1137
8. G. Medina-Gomez, and et al. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform Diabetes 54 2005 1706 1716
9. S. Sugii, and et al. PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization Proc. Natl. Acad. Sci. U.S.A. 106 2009 22504 22509
10. M. Schupp, and M.A. Lazar Endogenous ligands for nuclear receptors: digging deeper J. Biol. Chem. 285 2010 40409 40415
11. A.K. Haakonsson, and et al. Acute genome-wide effects of rosiglitazone on PPARgamma transcriptional networks in adipocytes Mol. Endocrinol. 27 2013 1536 1549
12. H. Gronemeyer, and et al. Principles for modulation of the nuclear receptor superfamily Nat. Rev. Drug Discov. 3 2004 950 964
13. E. Hu, and et al. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma Science 274 1996 2100 2103
14. L. Qiang, and et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma Cell 150 2012 620 632
15. S. Ji, and et al. O-GlcNAc modification of PPARgamma reduces its transcriptional activity Biochem. Biophys. Res. Commun. 417 2012 1158 1163
16. T. Ohshima, and et al. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification J. Biol. Chem. 279 2004 29551 29557
17. G.E. Kilroy, and et al. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal Obesity 17 2009 665 673
18. S.E. Step, and et al. Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARgamma-driven enhancers Genes Dev. 28 2014 1018 1028
19. S.A. Kliewer, and et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proc. Natl. Acad. Sci. U.S.A. 94 1997 4318 4323
20. G. Krey, and et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Mol. Endocrinol. 11 1997 779 791
21. S. Sauer Amorfrutins: a promising class of natural products that are beneficial to health Chembiochem 15 2014 1231 1238
22. J.B. Bruning, and et al. Partial agonists activate PPARgamma using a helix 12 independent mechanism Structure 15 2007 1258 1271
23. W. Zheng, and et al. Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor gamma (PPARgamma) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes Diabetologia 56 2013 401 411
24. V. Chandra, and et al. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA Nature 456 2008 350 356
25. P. Tontonoz, and B.M. Spiegelman Fat and beyond: the diverse biology of PPARgamma Annu. Rev. Biochem. 77 2008 289 312
26. G. Rizzo, and S. Fiorucci PPARs and other nuclear receptors in inflammation Curr. Opin. Pharmacol. 6 2006 421 427
27. R.E. Soccio, and et al. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes Cell Metab. 20 2014 573 591
28. G.S. Hotamisligil, and et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance Science 271 1996 665 668
29. M.F. Gregor, and G.S. Hotamisligil Inflammatory mechanisms in obesity Annu. Rev. Immunol. 29 2011 415 445
30. X. Prieur, and et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice Diabetes 60 2011 797 809
31. H. Zhang, and et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc. Natl. Acad. Sci. U.S.A. 102 2005 9406 9411
32. M. Ricote, and C.K. Glass PPARs and molecular mechanisms of transrepression Biochim. Biophys. Acta 1771 2007 926 935
33. S.W. Chung, and et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B J. Biol. Chem. 275 2000 32681 32687
34. H. Ruan, and et al. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB J. Biol. Chem. 278 2003 28181 28192
35. D. Kelly, and et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA Nat. Immunol. 5 2004 104 112
36. Y. Hou, and et al. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65 Nat. Commun. 3 2012 1300
37. R. Nielsen, and et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis Genes Dev. 22 2008 2953 2967
38. R.M. Evans, and et al. PPARs and the complex journey to obesity Nat. Med. 10 2004 355 361
39. B. Pourcet, and et al. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis Expert Opin. Emerg. Drugs 11 2006 379 401
40. J. Sakamoto, and et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochem. Biophys. Res. Commun. 278 2000 704 711
41. C. Weidner, and et al. Amorfrutins are potent antidiabetic dietary natural products Proc. Natl. Acad. Sci. U.S.A. 109 2012 7257 7262
42. V.G. Maltarollo, and et al. Structure-based virtual screening and discovery of new PPARdelta/gamma dual agonist and PPARdelta and gamma agonists PLoS ONE 10 2015 e0118790
43. J.M. Lehmann, and et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
44. F. Lalloyer, and B. Staels Fibrates, glitazones, and peroxisome proliferator-activated receptors Arterioscler. Thromb. Vasc. Biol. 30 2010 894 899
45. R.T. Nolte, and et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma Nature 395 1998 137 143
46. A. Natali, and E. Ferrannini Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review Diabetologia 49 2006 434 441
47. E. Phielix, and et al. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact Trends Pharmacol. Sci. 32 2011 607 616
48. J.M. Ye, and et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin Diabetologia 47 2004 1306 1313
49. H. Hauner The mode of action of thiazolidinediones Diab. Metab. Res. Rev. 18 Suppl. 2 2002 S10 S15
50. J.R. Colca, and et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer Clin. Pharmacol. Ther. 93 2013 352 359
51. A.S. Divakaruni, and et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier Proc. Natl. Acad. Sci. U.S.A. 110 2013 5422 5427
52. D.L. Feinstein, and et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70 2005 177 188
53. C. Rousseaux, and et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma J. Exp. Med. 201 2005 1205 1215
54. L. Dubuquoy, and et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases Gut 55 2006 1341 1349
55. L. Fuhr, and et al. Amorfrutins are natural PPARγ agonists with potent anti-inflammatory properties J. Nat. Prod. 78 2015 1160 1164
56. M.J. Khandekar, and et al. Molecular mechanisms of cancer development in obesity Nat. Rev. Cancer 11 2011 886 895
57. P.D. Home, and et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
58. K.G. Tolman The safety of thiazolidinediones Expert Opin. Drug Saf. 10 2011 419 428
59. S. Kean Planned study of Avandia in doubt after FDA review Science 329 2010 375
60. J. Woodcock, and et al. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration N. Engl. J. Med. 363 2010 1489 1491
61. M. McCarthy US regulators relax restrictions on rosiglitazone BMJ 347 2013 f7144
62. M. Mitka FDA eases restrictions on the glucose-lowering drug rosiglitazone JAMA 310 2013 2604
63. S.E. Kahn, and et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N. Engl. J. Med. 355 2006 2427 2443
64. J.A. Dormandy, and et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
65. C.A. Schneider, and et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease J. Am. Soc. Nephrol. 19 2008 182 187
66. I. Tzoulaki, and et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ 339 2009 b4731
67. A.K. McDonough, and et al. The effect of thiazolidinediones on BMD and osteoporosis Nat. Clin. Pract. Endocrinol. Metab. 4 2008 507 513
68. C. Vallarino, and et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights Clin. Drug Invest. 33 2013 621 631
69. J.F. Tobin, and L.P. Freedman Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy Trends Endocrinol. Metab. 17 2006 284 290
70. B.L. Balint, and L. Nagy Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases Endocr. Metab. Immune Dis. Drug Targets 6 2006 33 43
71. L.S. Doshi, and et al. Discovery and development of selective PPAR-gamma modulators (SPPAR-gamma Ms) as safe and effective antidiabetic agents Expert Opin. Invest. Drug 19 2010 489 512
72. C. Weidner, and et al. Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with potent glucose-lowering properties Diabetologia 56 2013 1802 1812
73. I.S. Aidhen, and et al. A common building block for the syntheses of amorfrutin and cajaninstilbene acid libraries toward efficient binding with peroxisome proliferator-activated receptors Org. Lett. 17 2015 194 197
74. M. Schupp, and et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity Diabetes 54 2005 3442 3452
75. A. Benardeau, and et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes Bioorg. Med. Chem. Lett. 19 2009 2468 2473
76. Y.K. Loke, and et al. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies BMJ 342 2011 d1309
77. J.H. Choi, and et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation Nature 477 2011 477 481
78. S.S. Choi, and et al. A novel non-agonist peroxisome proliferator-activated receptor gamma (PPARgamma) ligand UHC1 blocks PPARgamma phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity J. Biol. Chem. 289 2014 26618 26629
79. L. Guasch, and et al. Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation PLoS ONE 7 2012 e50816
80. W. Jiang, and et al. SIRT1 protects against apoptosis by promoting autophagy in degenerative human disc nucleus pulposus cells Sci. Rep. 4 2014 7456
81. X. Xie, and et al. L312, a novel PPARgamma ligand with potent anti-diabetic activity by selective regulation Biochim. Biophys. Acta 1850 2015 62 72
82. P. Li, and et al. Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity Cell 147 2011 815 826
83. A.S. Banks, and et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma Nature 517 2015 391 395
84. J.P. Thaler, and et al. Obesity is associated with hypothalamic injury in rodents and humans J. Clin. Invest. 122 2012 153 162
85. B. Finan, and et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci. Transl. Med. 5 2013 209ra151
86. B. Finan, and et al. Targeted estrogen delivery reverses the metabolic syndrome Nat. Med. 18 2012 1847 1856
87. M.O. Dietrich, and T.L. Horvath A marriage made to last in drug design Nat. Med. 18 2012 1737 1738
88. B. Finan, and et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents Nat. Med. 21 2015 27 36
89. C. Stahn, and et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists Mol. Cell. Endocrinol. 275 2007 71 78
90. A. Kharitonenkov FGFs and metabolism Curr. Opin. Pharmacol. 9 2009 805 810
91. A.L. Wu, and et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1 Sci. Transl. Med. 3 2011 113ra126
92. M. Ezzati, and E. Riboli Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals Science 337 2012 1482 1487
93. C. Weidner, and et al. Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice Mol. Nutr. Food Res. 58 2014 903 907
94. C. Weidner, and et al. Antidiabetic effects of chamomile flowers extract in obese mice through transcriptional stimulation of nutrient sensors of the peroxisome proliferator-activated receptor (PPAR) family PLoS ONE 8 2013 e80335
95. H. Wagner, and G. Ulrich-Merzenich Synergy research: approaching a new generation of phytopharmaceuticals Phytomedicine 16 2009 97 110
96. M. Rafraf, and et al. Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes J. Endocrinol. Invest. 38 2015 163 170
97. J. Lamb, and et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
98. D. Meierhofer, and et al. Protein sets define disease states and predict in vivo effects of drug treatment Mol. Cell. Proteomics 12 2013 1965 1979
99. D. Meierhofer, and et al. Integrative analysis of transcriptomics, proteomics, and metabolomics data of white adipose and liver tissue of high-fat diet and rosiglitazone-treated insulin-resistant mice identified pathway alterations and molecular hubs J. Proteome Res. 13 2014 5592 5602
100. S. Sauer Protein set analyses: how could this impact the clinic? Expert Rev. Proteomics 10 2013 305 307
101. D.D. Sears, and et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization Proc. Natl. Acad. Sci. U.S.A. 106 2009 18745 18750
102. K.K. Ryan, and et al. A role for central nervous system PPAR-gamma in the regulation of energy balance Nat. Med. 17 2011 623 626
103. M. Lu, and et al. Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones Nat. Med. 17 2011 618 622
104. M.G. Myers Jr, and C.F. Burant PPAR-gamma action: it's all in your head Nat. Med. 17 2011 544 545
105. G.A. Michelotti, and et al. NAFLD, NASH and liver cancer Nat. Rev. Gastroenterol. Hepatol. 10 2013 656 665
106. S.C. Hasenfuss, and et al. Regulation of steatohepatitis and PPARgamma signaling by distinct AP-1 dimers Cell Metab. 19 2014 84 95